Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (2230)	6/14/2003 9:53:33 PM
From: ACAN	Read Replies (2) \| Respond to of 23958

Godot; I'd like to put forward CTE cardiotech at 2.79. it has a novel microporous polyurethane covered stent material, which would adapt itself to drug release well. Theyare looking for a licensing agreement, and through Gish biomedical have recently brought out innovative cardiac and cardiopulmonary products in some of the most lucrative areas of the world for their heart lung bypass products. Many of the products are one time use disposable products, There are several other dressing products in the pipeline. Gish is a wholly owned subsidiary of CTE and last Quarter turned profitable and introduced a new cardioplegia device on June 10 biz.yahoo.com In light of recent moves in Boston Scientific , there may be considerable interest quickly in a licensing agreement, or even a buyout at these levels. Very lucrative market. with 11 million americans with coronary heart disease. Do you like it? Allan